

The Hippo Pathway: Signaling, Cancer, and Beyond

May 8-11, 2019 | San Diego, CA

AACR American Association for Cancer Research

Poster Session A

Thursday, May 9

12:30-2:30 pm

A01 YAP1 drives ependymoma-like tumour formation in the brain. Noreen Eder, The Francis Crick Institute, London, United Kingdom.

A02 YAP1 opposes differentiation in mesenchymal tumors. T.S. Karin Eisinger-Mathason, University of Pennsylvania, Philadelphia, PA.

A03 Generation of primary sarcoma mouse models through CRISPR/Cas9 mediated activation of Yap1. Jianguo Huang, Duke University, Durham, NC.

A04 Genetic and pharmacologic inhibition of HES1 reduces YAP1 expression, impairing rhabdomyosarcoma cell growth. Alexander Kovach, Duke University, Durham, NC.

A05 RAS signaling promotes ERMS cell viability via sustaining TAZ expression and protein stability. Liz (Yi-Tzu) Lin, Duke University Medical Center, Durham, NC.

A06, PR03 YAP/TAZ requirement in mesenchyme-originated intestinal hamartomatous polyposis. Junhao Mao, University of Massachusetts Medical School, Worcester, MA.

A07 Role of YAP/TEAD and YAP/Smad signaling pathways in osteosarcoma tumour growth and lung metastasis dissemination. Sarah Morice, INSERM, Nantes, France.

A08 Loss of non-canonical Hippo signaling in fusion-positive alveolar rhabdomyosarcoma increases invasiveness and a dedifferentiated phenotype associated with metastasis. Kristianne Oristian, Duke University Medical Center, Durham, NC.

A09 Targeting Hippo-dependent and Hippo-independent regulation of the YAP1 oncoprotein in childhood rhabdomyosarcoma. Katherine Slemmons, Children's Hospital Los Angeles, Los Angeles, CA.

A10 Taz regulates aging of hematopoietic stem cells. Anna Mura-Meszaros, Leibniz Institute on Aging, Jena, Germany.

A11 Reawakening the regenerative potential of mammalian Müller glial cells to restore sight. Ross Poche, Baylor College of Medicine, Houston, TX.

A12 YAP and cancer stem cells in basal-like breast cancer. Hazel Quinn, MDC Berlin, Berlin, Germany.

A13 Yap activity in bile ducts, but not in hepatocytes, is required for normal liver regeneration. Elisabeth Verboven, VIB - KULeuven, Leuven, Belgium.

A14, PR10 Hippo Regulates Intestinal Regeneration By Inducing Revival Stem Cells. Jeff Wrana, Lunenfeld-Tanenbaum Research Institute, Toronto, Ontario, Canada.

A15 A balance of yki/sd activator and e2f1/sd repressor complexes controls cell survival and affects organ size. Peng Zhang, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.

A16 The α-Arrestin ARRDC3 functions as a metastasis suppressor by regulating GPCR activation of the Hippo pathway. Aleena Arakaki, UC San Diego, San Diego, CA.

A17 The Tyrosine Phosphatase SHP2 regulates YAPY357 Phosphorylation, Sub-cellular Localization, and Transcriptional Co-Activity in Cholangiocarcinoma. EeeLN Buckarma, Mayo Clinic, Rochester, MN.

A18 Location, location, location: Avenues to regulating Hippo. Philamer C Calses, Genentech Inc., South San Francisco, CA.

A19 Regulation of glioblastoma tumor growth and stem cell properties through Gα12 and tissue factor, upstream and downstream players in YAP signaling. Olga Chaim, UCSD, La Jolla, California.

A20 Gαq controls the Hippo Pathway through MOB1 tyrosine phosphorylation by FAK. Xiaodong Feng, Moores Cancer Center, University of California, San Diego, La Jolla, California.

A21, PR02 Spatial resets modulate YAP-dependent transcription. Matt Franklin, Stanford University, Stanford, CA.

A22, PR04 Integrin-mediated mechano-transduction controls HER2 oncogenic signaling and activation of YAP in breast cancer. Filippo Giancotti, UT MD Anderson Cancer Center, Houston, TX.

A23 Verteporfin as a new treatment paradigm for platinum-resistant ovarian cancer cells. Radhika Gogoi, Geisinger Clinic, Danville, PA.

A24 Functional annotation of the Hippo somatic mutations in human cancer. Han Han, Department of Development and Cell Biology, University of California, Irvine, Irvine, CA.

A25, PR06 Mechanistic Insights for TEAD/YAP Activation. Jeffrey Holden, Genentech, South San Francisco, CA.

A26 Classification of glioblastoma tumorsphere depending on the regulatory mechanisms of the Hippo pathway. Seok-Gu Kang, Departments of Neurosurgery, Brain Tumor Center, Severance Hospital, Yonsei University College of Medicine, Seoul, Seoul, Korea.

A27 Increasing proximity triggers Mst2 autophosphorylation. Jennifer Kavran, Johns Hopkins School of Public Health, Baltimore, MD.

A28 DEAD-box RNA helicase DP103 enhances YAP sumoylation for YAP-TEAD dependence and statin sensitivity in triple negative breast cancer. Xianning Lai, Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.

A29 Genome-wide CRISPR/Cas9 screens for the identification of novel YAP1/TAZ modulators. Martin Lange, Bayer AG, Research & Development, Pharmaceuticals Division, Berlin, Germany.

A30 Super-enhancer-associated Long Noncoding RNA UCA1 Interacts Directly with AMOT to Inhibit Hippo Signaling Pathway in Epithelial Ovarian Cancer. Xianzhi Lin, Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA.

A31 Transcriptional addiction to YAP1 -a major driving force of oral cancer carcinogenesis and evolution ? Muneyuki Masuda, Department of Head and Neck Surgery, National Kyushu Cancer Cente, Fukuoka, Fukuoka, Japan.

A32 The small GTPase Rac1 controls the stability of Yes-Associated Protein (YAP) independently of the LATS1/2 kinases. Chitra Palanivel, University of Nebraska Medical Center, Omaha, NE.

A33, PR01 Regulation of TEAD by p38 MAPK-induced cytoplasmic translocation. Hyun Woo Park, Yonsei University, Seoul, South Korea.

A34 Identification of a MAP kinase that regulates YAP abundance. Sanghyun Park, KAIST, Daejeon, Republic of Korea.

A35 Title: Regulation of the Hippo signaling pathway through ubiquitin-mediated degradation of TEAD transcription factors. Trang Pham, Genentech, South San Francisco, CA.

A36 Paracrine orchestration of intestinal tumorigenesis at the mesenchymal-epithelial interface. Manolis Roulis, Yale School of Medicine, New Haven, CT.

A37 Implication of targeting YAP1 in KRAS-mutant lung cancer cells. Iwao Shimomura, National Cancer Center Research Institute, Tokyo, Japan.

A38 A 4-gene YAP-related pathway expression signature informs about dependence of tumors on Hippo pathway signaling. Dirk Wienke, Merck KGaA, Biopharma, R&D, Darmstadt, Germany.

A39, PR09 The Hippo pathway integrates PI3K-Akt signals with mechanical cues to control tissue growth. Barry Thompson, Francis Crick Institute, London, England, United Kingdom.

A40 Hippo signaling in cancer development. Wenqi Wang, University of California, Irvine, Irvine, CA.

A41 Inhibition of aberrant YAP and TAZ activity to prevent metastasis formation and growth. Janine Warren, Albany Medical College, Albany, NY.

A43 Identification of novel YAP/TAZ regulators in metastatic cancer. Yuxuan Xiao, Albany Medical College, Albany, NY.

A44 PR55α regulatory subunit of PP2A inhibits the MOB1/LATS cascade and activates YAP in pancreatic cancer cells. Ying Yan, University of Nebraska Medical Center, Omaha, NE.



The Hippo Pathway: Signaling, Cancer, and Beyond
May 8-11, 2019 | San Diego, CA

AACR American Association for Cancer Research

Poster Session B

Friday, May 10

4:30-6:30 pm

B01 Understanding the LATS1 pro-apoptotic signalling network in melanoma. Lucia Garcia-Gutierrez, Systems Biology Ireland, University College Dublin, Dublin, Ireland.

B02 Elevated YAP expression associates with EMT, stem-ness andangiogenic properties of TNBC cell lines and recurrence in TNBC patients. Madhura Kulkarni, Center for Translational Cancer Research, IISER Pune and PCCM, Pune, MH, India.

B03 Differential YAP expression in glioma cells induces cell competition and promotes tumorigenesis. Zhijun Liu, Duke University, Durham, NC.

B04 Hepatic cholesterol upregulates TAZ in nonalcoholic steatohepatitis. Xiaobo Wang, Columbia University, New York, NY.

B05 Investigating the role of STK3/4 kinases in cancer. Nicole Bata, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA.

B06 Development of selective LATS1/LATS2 inhibitors for the pharmacological modulation of the hippo signaling pathway. Michele Ceribelli, National Center for Advancing Translational Sciences (NCATS), NIH, Rockville, MD.

B07 NUAK2 inhibition for prostate cancer. Weiwei Fu, Duke University Medical Center, Durham, NC.

B08 Therapeutic inhibition of YAP1 expression by next generation antisense oligonucleotides leads to antitumor activity in head and neck squamous cell carcinoma with YAP1 activation. Youngsoo Kim, Ionis Pharmaceuticals Inc., Carlsbad, CA.

B09 Selective depletion of YAP1 with next generation (constrained ethyl-cEt) antisense oligonucleotides results in tumor regression in mouse models of HCC with YAP1 activation. Youngsoo Kim, Ionis Pharmaceuticals Inc., Carlsbad, CA.

B10 Evaluating YAP and TAZ as therapeutic targets for treating Malignant Mesothelioma with Hippo pathway disruptions. Aishwarya Kulkarni, The Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

B11 Computational insights on the druggability of TEAD YAP-binding domain. Chenglong Li, University of Florida, Gainesville, Florida.

B12 High-throughput screening platform to discover TEAD modulators. Sungho Moon, Yonsei University, Seoul, Republic of Korea.

B13 Cancer metabolism sensitizes metformin treatment by targeting the Hippo-YAP/TAZ pathway. Jae Hyung Park, Yonsei University, Seoul, Republic of Korea.

B14 Discovery of YAP-TEAD Protein-Protein Interaction inhibitors (PPI) for treating Malignant Pleural Mesothelioma (MPM). Anne Soudé, Inventiva, Daix, France.

B15, PR07 Targeting the Hippo-YAP pathway with small molecule compounds. Tracy Tang, Vivace Therapeutics, San Mateo, CA.

B16 Silence of Hippo pathway induces pro-tumoral immunity: New therapeutic target of glioblastomas. Eui Hyun Kim, Department of Neurosurgery, Severance Hospital, Brain Tumor Center, Yonsei University College of Medicine, Seoul, Seoul, South Korea.

B17 Hyperactivating the Hippo pathway effector TAZ distorts the immune microenvironment in promoting the mesenchymal transformation in glioblastoma. Wei Li, Penn State College of Medicine, Hershey, PA.

B18 YAP1 and TAZ mediate BET inhibitor-dependent immune regulation in NSCLC. Francesca Reggiani, AUSL-IRCCS, Reggio Emilia, Italy.

B19 Neurofibromin 2 regulates metabolism in the heart. Dominic Del Re, Rutgers New Jersey Medical School, Newark, NJ.

B20 STK3/4-mediated phosphorylation of LC3B regulates directional intracellular transport of autophagic vesicles. Jose L. Nieto Torres, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA.

B21 Proteomic profiling of tandem affinity purified MAP4K family kinases. Gayoung Seo, University of California, Irvine, California.

B22 The origin of the hippo pathway. Yuxuan Chen, University of California, Irvine, CA.

B23 A novel model of neurofibroma that deciphers its developmental origin and susceptibility to modification by the hippo pathway. Zhiguo Chen, University of Texas Southwestern Medical Center, Dallas, TX.

B24 Identification of YAP modulators using genome-wide gain-of-function screening. Paul Cramer, Leibniz Institute on Aging – Fritz Lipmann Institute, Jena, Germany.

B25 An actionable AXL-ABL2-TAZ signaling axis promotes lung adenocarcinoma metastasis to the brain. Jacob Hoj, Duke University, Durham, North Carolina.

B26 A tumor specific molecular network promotes tumor growth by enforcing a JNK-YKI feed forward loop. Madhuri Kango-Singh, Department of Biology, University of Dayton, Dayton, OH.

B27 IDENTIFICATION OF UVEAL MELANOMA DISSEMINATED CANCER CELL DORMANCY MECHANISMS. Melisa Lopez-Anton, Division of Hematology and Oncology, Department of Medicine, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.

B28 Cep55 regulates YAP/TAZ expression and localization during cell cycle progression. Pin Ouyang, Chang Gung University, Taoyuan, Taoyuan, Taiwan.

B29 AXL Inhibitor TP-0903 attenuates TGFβ–Hippo signaling in lung adenocarcinoma cells. Josephine Taverna, UT Health Science Center San Antonio, San Antonio, Texas.

B30 Joint control of epidermal cell fate by Yorkie and Bonus. Alexey Veraksa, UMass Boston, Boston, MA.

B31 YAP1-induced Cervical Carcinogenesis Challenges the HPV Dogma. Cheng Wang, Massachusetts General Hospital / Harvard Medical School, Boston, MA.

B32 High-throughput chemical screening reveals YAP-mediated alterations in drug sensitivities. Andrew Bondesson, University of Washington, Seattle, WA.

B33 Genome Scale CRISPR/cas9 screening identifies Hippo pathway as key determinant for susceptibility to BET inhibitors in lung cancer. Giulia Gobbi, AUSL-IRCCS, Reggio Emilia, Italy.

B34, PR11 Active YAP as a functional marker of drug-tolerant persister cells in EGFR-mutant and ALK fusion positive NSCLC. Franziska Haderk, UCSF, San Francisco, CA.

B35 FLT3-TAZ signaling induces drug resistance in leukemia. Ji Eun Shin, Yonsei University, Seoul, Republic of Korea.

B36 Therapy-induced YAP hyperactivation is a mechanism driving the evolution of residual disease and resistance to targeted cancer therapy. Aubhishek Zaman, UCSF, San Francisco, CA.

B37 Genomic view of YAP1 dependent transcription. Stefano Campaner, Center for Genomic Science of IIT@SEMM, Fondazione Istituto Italiano di Tecnologia (IIT), Milan, Italy.

B38, PR08 Systematic pan-cancer analyses of Hippo Pathway deregulation in cancer. Matthew Chang, Genentech, South San Francisco, CA.

B39 The SWI/SNF complex is a mechanoregulated inhibitor of YAP and TAZ. Michelangelo Cordenonsi, University of Padova, Padova, Italy.

B40, PR05 Genome-wide screening identifies novel YAP modulators. Dana Elster, Leibniz Institute on Aging, Fritz Lipmann Institute e.V., Jena, Thüringen, Germany.

B41 Role of AIB1 in YAP-TEAD Signaling in the Progression of Early Stage Breast Cancer. Max Kushner, Georgetown University, Washington, DC.

B42 YAP1/Hippo pathway and SWI/SNF as critical players in squamous cancers and normal development. Srinivas Vinod Saladi, MEEI/MGH/HMS, Boston, MA.

B43 Division of labor between YAP and TAZ in lung cancer. Michal Shreberk-Shaked, Weizmann Institute of Science, Rehovot, Israel.

B44 The TAZ-CAMTA1 and YAP-TFE3 fusion proteins transform cells by binding to subunits of the histone acetyltransferase Ada2a-containing complex (ATAC). Munir Tanas, Department of Pathology, University of Iowa, Iowa City, IA.